ArticleBiotechnology and bioengineering2020
Multiorgan microfluidic platform with breathable lung chamber for inhalation or intravenous drug screening and development.
Article in Biotechnology and bioengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- An eighteen-organ microphysiological system coupling a vascular network and excretion system for drug discovery.Microsystems & nanoengineering · 2025Article
- Development of a Microphysiological System to Model Human Cancer Metastasis From the Colon to the Liver.Biotechnology and bioengineering · 2025Article
- Multi-cellular engineered living systems to assess reproductive toxicology.Reproductive toxicology (Elmsford, N.Y.) · 2024Review
- Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models.International journal of molecular sciences · 2023Review
- Organ-on-a-chip meets artificial intelligence in drug evaluation.Theranostics · 2023Review
- What Can an Organ-on-a-Chip Teach Us About Human Lung Pathophysiology?Physiology (Bethesda, Md.) · 2022Review
- Liver microphysiological platforms for drug metabolism applications.Cell proliferation · 2021Review
- Enhanced Microfluidic Sample Homogeneity and Improved Antibody-Based Assay Kinetics Due to Magnetic Mixing.ACS sensors · 2021Article
- Diversity Models and Applications of 3D Breast Tumor-on-a-Chip.Micromachines · 2021Review
- Breast tumor-on-chip models: From disease modeling to personalized drug screening.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Multifunctional microfluidic chip for cancer diagnosis and treatment.Nanotheranostics · 2021Review
- Preclinical Development of Orally Inhaled Drugs (OIDs)-Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models?Animals : an open access journal from MDPI · 2020Article
- Simulation of nanoparticle transport and adsorption in a microfluidic lung-on-a-chip device.Biomicrofluidics · 2020Article
- Microphysiological Systems: Design, Fabrication, and Applications.ACS biomaterials science & engineering · 2020Article
- New Approach Methods to Evaluate Health Risks of Air Pollutants: Critical Design Considerations for In Vitro Exposure Testing.International journal of environmental research and public health · 2020Review
- Modifying and IntegratingFrontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Efficient and economical delivery of pharmaceuticals to patients is critical for effective therapy. Here we describe a multiorgan (lung, liver, and breast cancer) microphysiological system ("Body-on-a-Chip") designed to mimic both inhalation therapy and/or intravenous therapy using curcumin as a model drug. This system is "pumpless" and self-contained using a rocker platform for fluid (blood surrogate) bidirectional recirculation. Our lung chamber is constructed to maintain an air-liquid interface and contained a "breathable" component that was designed to mimic breathing by simulating gas exchange, contraction and expansion of the "lung" using a reciprocating pump. Three cell lines were used: A549 for the lung, HepG2 C3A for the liver, and MDA MB231 for breast cancer. All cell lines were maintained with high viability (>85%) in the device for at least 48 hr. Curcumin is used to treat breast cancer and this allowed us to compare inhalation delivery versus intravenous delivery of the drug in terms of effectiveness and potentially toxicity. Inhalation therapy could be potentially applied at home by the patient while intravenous therapy would need to be applied in a clinical setting. Inhalation therapy would be more economical and allow more frequent dosing with a potentially lower level of drug. For 24 hr exposure to 2.5 and 25 µM curcumin in the flow device the effect on lung and liver viability was small to insignificant, while there was a significant decrease in viability of the breast cancer (to 69% at 2.5 µM and 51% at 25 µM). Intravenous delivery also selectively decreased breast cancer viability (to 88% at 2.5 µM and 79% at 25 µM) but was less effective than inhalation therapy. The response in the static device controls was significantly reduced from that with recirculation demonstrating the effect of flow. These results demonstrate for the first time the feasibility of constructing a multiorgan microphysiological system with recirculating flow that incorporates a "breathable" lung module that maintains an air-liquid interface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.